[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Aberdeen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":592},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,43,66,87,112,151,182,207,232,253,275,295,315,337,358,390,416,439,459,484,503,521,551,572],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100600489","neural-correlates-of-autistic-individuals-with-anorexia-nervosa-100600489",false,"NCT07098156","Neural Correlates of Autistic Individuals With Anorexia Nervosa","Neuroanatomical Differences Associated With Anorexia Nervosa and Masking Behaviour in Autistic Individuals","Inclusion Criteria:\n\nHealthy Autistic Individuals (Autistic Controls) must:\n\n* Be aged 25-45 years\n* Be Autistic (clinically diagnosed and\u002For have an Autism Quotient (AQ-10) score of ≥6)\n* Be able to provide informed consent for the study\n* Be able to read, understand and respond to questionnaires in English\n* Have no history of an eating disorder\n* Willing to have an MRI scan in Aberdeen\n\nAutistic Individuals with anorexia nervosa must:\n\n* Be aged 25-45 years\n* Be Autistic (clinically diagnosed and\u002For have an AQ-10 score of ≥6)\n* Be able to provide informed consent to the study\n* Be able to read, understand and respond to questionnaires in English\n* Have a diagnosis of anorexia nervosa or a body mass index of \\\u003C18.5\n* Willing to have an MRI scan in Aberdeen\n\nExclusion Criteria:\n\nIndividuals are not eligible for the study if they:\n\n* Are aged \\\u003C25 or \\>45 years\n* Are not Autistic or not clinically diagnosed as Autistic and have an AQ-10 score of \\\u003C6\n* Are diagnosed with an eating disorder other than anorexia nervosa\n* Have a history of brain injury (e.g., stroke)\n* Be unable to provide informed consent for the study\n* Have contraindications to MRI scanning, such has implantable cardiac devices\n* Are unable to read, understand and respond to questionnaires in English\n* As participants will need to consent to the study and complete questionnaires by themselves, individuals with intellectual disability will be excluded from this study","ALL","25 Years","45 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","Masking is a behaviour or strategy used by many Autistic people to appear non-Autistic and blend in with a neurotypical society. The goal of this observational study is to understand the relationship between masking, anorexia nervosa symptoms and brain structure in Autistic people. The main questions this study aims to answer are:\n\n* Do Autistic individuals with anorexia nervosa show differences in structure or function of the brain relation to Autistic individuals without anorexia nervosa?\n* Do Autistic individuals with anorexia nervosa display higher levels of masking than Autistic individuals without anorexia nervosa?\n* Are there indeed relationships between levels of masking, anorexia nervosa symptoms and brain structure in Autistic people?\n\nResearchers will compare Autistic people without anorexia nervosa to Autistic people with anorexia nervosa to see if there are differences between groups. Participants will:\n\n* Complete a series of questionnaires focused on eating disorder symptoms, autistic traits, autistic masking and psychological well-being\n* Undergo an MRI scan at the Aberdeen Royal Infirmary",[25,26],"Autism","Anorexia Nervosa",[28,29],"MRI","Magnetic Resonance Imaging","RECRUITING","2026-05-04",{"date":33,"type":34},"2026-05-05","ACTUAL",{"date":36,"type":34},"2025-07-15",{"date":38,"type":21},"2026-07-31",{"name":40,"class":41},"University of Aberdeen","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100588935","puffins-brain-health-study-100588935","NCT06947876","PUFFINS Brain Health Study","Proving the Utility of Ultra-low Field MRI for Assessing Brain Health","PUFFINS BH","Inclusion Criteria:\n\n* Adults ≥ 50 years old.\n* Subjects who do not report problems with memory.\n* Small vessel disease (Fazekas score 1 to 3).\n* Suitable body habitus.\n* Able to understand written and spoken English.\n\nExclusion Criteria:\n\n* History of major stroke (minor stroke\u002FTransient Ischaemic Attacks or lacunar stroke are acceptable).\n* Individuals unable to give informed consent.\n* Contra-indications to MRI scanning such as implantable cardiac devices.","50 Years",{"count":53,"type":21},85,"Small vessel disease (SVD) is a major cause of stroke and contributor to dementia cases. As work continues to develop new treatments to address the impact of SVD, new imaging techniques are needed to identify and track the progression of brain changes that occur with SVD. Magnetic Resonance Imaging (MRI) is the gold standard to diagnose poor brain health due to small vessel disease. However, current MRI systems are expensive and complex to operate, and so access is limited.\n\nLow-field MRI technology, operating at magnetic field strengths many times lower than conventional MRI, can make brain imaging much more cost-effective and accessible. However, further work is needed to develop low-field MRI towards clinically feasible assessments of brain health. The University of Aberdeen hosts a unique network of researchers and imaging technologies that is now making it possible to test and develop different low-field MRI approaches towards solving key healthcare challenges.\n\nThe aim of this study is to evaluate the potential of two distinct approaches, field-cycling imaging (FCI) and ultra-low field MRI (ULF-MRI), to detect brain changes linked with small vessel disease. Automated methods will be developed to analyse images and extract measurements that detect and track progression of disease severity.",[56],"Cerebral Small Vessel Disease",[58,59],"Field-cycling imaging","Ultra-low field MRI",{"date":33,"type":34},{"date":62,"type":34},"2025-12-17",{"date":64,"type":21},"2027-05",{"name":40,"class":41},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100496173","chemotherapy-induced-cognitive-impairment-100496173","NCT05740787","Chemotherapy Induced Cognitive Impairment","Inflammatory and Neural Correlates of Chemotherapy-Induced Cognitive Impairment: A Pilot Study","CONCERT","Inclusion Criteria:\n\n* Women and men \\>18 years\n* Diagnosed with HER2 negative breast cancer\n* Receiving EC-Taxane or Taxane only based chemotherapy\n* Able to communicate in English\n* Willing and able to give informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Any patient whose physical condition will preclude them from lying still for the duration of the brain scan.\n* pre-excisting mental condition\u002Fdisability\n* Contraindication to magnetic resonance scanning such as an implantable cardiac device.","18 Years",{"count":20,"type":21},"Chemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of \"chemo fog\" also known as \"chemobrain\" has not been fully investigated and is often based on comments of breast cancer patients attending outpatient clinics during and after their chemotherapy. Changes in thinking ability like lack of concentration, loss of memory and the inability to hold a thought or even a conversation has a significant impact on the lives of breast cancer patients. Without understanding what \"chemobrain\" is, and what causes it, there is little that doctors can do to help at the moment.\n\nThe team proposing this study believe that chemotherapy causes chemicals associated with inflammation to attack parts of the brain that are important for concentration and making new memories. Unfortunately, it is not possible to measure these chemicals directly in the brain, but we believe that a brain scan sensitive to excess iron, a marker of brain inflammation, can help. This project will measure thinking ability, such as memory and concentration, take a blood sample and do a brain scan before, during and after a patient has chemotherapy. We will then look for changes in iron in the brain areas that are important for concentration and memory and compare those to changes in thinking ability and to levels of inflammation chemicals in the blood. This information will be essential to help plan our next step which is to test ways to reduce the effects of \"chemobrain\".",[78],"Breast Cancer",{"date":80,"type":34},"2026-05-08",{"date":82,"type":34},"2022-12-15",{"date":84,"type":21},"2026-12-31",{"name":40,"class":41},1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":86},"100417693","periodontal-health-in-patients-acutely-admitted-for-myocardial-infarction-a-case-control-study-100417693","NCT04719026","PERIODONTAL HEALTH IN PATIENTS ACUTELY ADMITTED FOR MYOCARDIAL INFARCTION: A CASE CONTROL STUDY","PEDICAD","Inclusion Criteria:\n\n* cases: Patients aged 20-90 admitted with acute myocardial infarction\n* controls: Dental patients, aged 20-90, matched to patients in the case study group for age, gender (±7) and risk factors for coronary artery disease (hypertension, obesity, diabetes, smoking, hypercholesterolaemia) but with no history of myocardial infarction)\n\nExclusion Criteria:\n\n* Severe co-morbidities, Inability to consent, pregnant participants will be excluded, participants with other systemic inflammatory diseases, patients taking antimicrobials or antibiotics in last three years, patients taking medications, such as cyclosporine, calcium channel blockers, phenytoin, immunocompromised patients, patients with malignancies, patinets with type-2 or type-3 hypersensitivities","20 Years","90 Years",{"count":97,"type":21},320,"Heart attack remains a major cause of death in adult population worldwide and especially within Scotland. A large portion of the general population has an increased risk of suffering from a heart attack because of their genetic make-up, disease profile and lifestyle choices.\n\nLiterature suggests that apart from these known risk factors, long-standing inflammation (reaction of tissues to infection or injury) elsewhere in the body may be responsible for heart attacks. It has been suggested that gum disease may be one such condition. If left untreated, gum disease may expose the entire body to a long-term inflammatory burden where inflammatory molecules can disseminate from the gums into the bloodstream and affect various body structures. This study explores the influence of gum disease on the risk of heart attack by comparing the gum health of participants who recently had a heart attack to the gum health of participants with no history of heart problems after accounting for other risk factors. Findings will provide critical information for the design of our forthcoming study to establish the effect of treatment of gum disease on the risk of heart attack, and its cost-effectiveness. Ultimately this research will tackle another risk factor for heart attacks and thus inform enhancement of public health prevention strategies.",[100,101],"Myocardial Infarction, Acute","Periodontitis",[103,104,105],"myocardial infarction","coronary artery disease","periodontal diseases",{"date":80,"type":34},{"date":108,"type":34},"2018-02-16",{"date":110,"type":21},"2027-03-14",{"name":40,"class":41},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":16,"minAge":121,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":124,"conditions":125,"keywords":130,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":86},"100409599","scottish-advanced-fetal-research-study-100409599","NCT04613583","Scottish Advanced Fetal Research Study","Normal Development of the Human Fetus and the Influences and Mechanisms by Which That Development Occurs and is Perturbed","SAFeR","Inclusion Criteria:\n\n* Women at 7-20 weeks of gestation (critical stage of fetal development).\n* Women aged 16 years and older, deemed capable of making a rational decision.\n* Absence of fetal anomaly at ultrasound scan (only normal fetuses are required).\n* Women who are fluent English speakers. This is in order to ensure the woman understands that fetal tissues will be collected.\n\nExclusion Criteria:\n\n* Women exhibiting considerable emotional distress.\n* Fetal anomalies identified at ultrasound scan.",true,"16 Years",{"count":123,"type":21},1200,"In-utero exposure to drugs and chemicals through maternal smoking, alcohol use, drug abuse, prescription medicines and occupational\u002Flifestyle exposures is widespread. Such exposures can alter fetal development and programming, leading to the effects becoming \"locked in\" from birth and causing long-term adverse consequences for the individual. These include costly and widespread conditions such as obesity, hypertension, metabolic syndrome and infertility. The weight of evidence linking these conditions to fetal recreational drug or environmental chemical exposures, including cigarettes, alcohol, air pollution, food contact materials, is overwhelming. What is lacking is an understanding of how fetal drug exposure translates to adult ill-health and this is due, largely, to an inability to study the problem directly in affected human fetuses. The investigators, and others, have shown that human fetal development, which lays the foundations of adult health and function (fetal programming), is quite different from the rodent and frequently exhibits surprising aspects. It has become evident that the close interconnectivity of the developing fetal organs and also the placenta, means that a much more holistic approach to research aiming to understand human fetal development and the challenges posed to programming for a health adulthood is critical. To that end the investigators have established a carefully considered gestational age range (7-20 weeks of gestation) of fetuses we can study together with multiple fetal organs and body fluids collected and maternal information recorded.\n\nThe overarching objective of the study is to intensively and systematically study the human fetus during a normal pregnancy and pregnancies where aspects of maternal lifestyle and environment will challenge the fetus. The investigators aim to provide fundamental information to better understand the mechanisms involved and to detect and treat or ameliorate adverse effects during pregnancy (such as maternal smoking\u002Fdrinking, deprivation, exposure to pollution). In the long term findings from this research will be important for future studies aimed at enabling better health in later life.",[126,127,128,129],"Fetal Developmental Abnormality","Fetal Development","Human","Life Style",[131,132,133,134,135,136,137,138,139,140,141,142,143,144],"fetal","human","gestation","development","congenital","exposures","maternal","life style","exogenous chemicals","obesity","deprivation","alcohol","cigarette","endocrine disruption",{"date":33,"type":34},{"date":147,"type":34},"2016-05-01",{"date":149,"type":21},"2028-10-01",{"name":40,"class":41},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":120,"sex":16,"minAge":74,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":162,"phases":163,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":86},"100571008","drivers-and-barriers-for-adopting-healthy-and-sustainable-food-swaps-in-young-100571008","NCT06714656","Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young","Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young. The FOOD SWAPS Study","FOOD-SWAPS","Inclusion Criteria:\n\n* men and women\n* aged 18-30 years,\n* having a high baseline consumption of red meat (More than 70 grams per day or 280 grams per 4 days)\n* who are willing to make their diet healthier and more sustainable but do not know how or are facing barriers\n\nExclusion Criteria:\n\n* Having a lower red meat consumption (less than 70 grams per day or 240 grams per 4 days)\n* being vegetarian or vegan\n* having a clinical diagnosis of hypertension or high cholesterol, having unstable or untreated thyroid disorder\n* taking blood pressure and\u002For cholesterol-lowering medications (e.g. beta blockers or statins)\n* having food allergies, being on a weight loss diet or having lost \\>5kg in the last 6 months\n* having a history of an eating disorder.","30 Years",{"count":161,"type":21},30,"INTERVENTIONAL",[164],"NA","Food represents one of the greatest health and environmental challenges of the 21st century. Consuming less of the most environmentally damaging foods, such as meat, is considered an effective method to reduce food-related greenhouse gas emissions. The aim of these N-of-1 FOOD SWAP intervention studies is to investigate whether and which physiological, psychological and environmental factors, at an individual level, modify the adoption and adherence of food swaps aiming to reduce the intake of red meat and replace this with fish or plant-based foods, in young adults. The series of N-of-1 studies will also assess whether an 8-week food swap intervention will improve general health markers such as blood pressure, plasma lipids and glucose, and blood\u002Furinary metabotype. This approach will provide insight into physiological, behavioural and environmental factors that can help explain individual fluctuations in adherence and physiological outcomes common in nutrition studies. In the future, this should enable us to tailor how we deliver effective individualised interventions and better consider and control for factors affecting adherence and response to dietary interventions.",[167,168],"Diet Modification","Sustainable Food Consumption",[170,171,172,173],"diet","sustainable food choices","food swaps","N of 1 study","2026-04-30",{"date":176,"type":34},"2026-05-01",{"date":178,"type":34},"2024-12-09",{"date":180,"type":21},"2027-12-30",{"name":40,"class":41},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":199,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":86},"100627018","fci-glioblastoma-study-100627018","NCT07443176","FCI-Glioblastoma Study","Applying New MRI Technology to Improve Outcomes From Chemoradiotherapy Treatment for Adult Patients With Glioblastoma","Inclusion Criteria:\n\n* Patients scheduled to have standard adjuvant temozolomide treatment for glioblastoma, within four weeks following radical radiotherapy with concomitant temozolomide\n* 18 to 70 years old\n* Life expectancy at least 12 weeks\n* Able to undergo MRI scans lasting up to 1 hour each\n* On stable or reducing dose of steroids for at least 5 days\n* Able to provide informed consent\n* Able to understand written and spoken English\n\nExclusion Criteria:\n\n* Previous treatment for glioblastoma other than surgery and chemoradiation.\n* Previous radiotherapy to brain and\u002For prior chemotherapy for lower grade glioma.\n* Planned additional treatment with Tumor-Treating Fields\n* Previous cytotoxic wafers or implants at the time of neurosurgery\n* Uncontrolled intercurrent illness\n* Being pregnant or nursing\n* Conventional MRI contraindications\n* Known allergy to contrast agent\n* Unable to provide informed consent","70 Years",{"count":191,"type":21},18,"The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can tell the difference between tumour growth (progression) and 'pseudo-progression' (which looks like tumour but is not cancerous tissue) in patients with glioblastoma. The main question it aims to answer is:\n\n• Can FCI differentiate glioblastoma progression from pseudo-progression?\n\nParticipants will undergo a standard MRI scan and an FCI scan, three times during the study. One before starting adjuvant chemotherapy, another one after three cycles and one at the end of treatment.",[194],"Glioblastom WHO Grade 4",[196,197,198,28],"Glioblastoma","Field-Cycling Imaging","FCI","NOT_YET_RECRUITING","2026-04-29",{"date":174,"type":34},{"date":203,"type":21},"2026-05",{"date":205,"type":21},"2027-12",{"name":40,"class":41},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":215,"minAge":74,"maxAge":189,"enrollmentInfo":216,"targetDuration":4,"studyType":162,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":42},"100598382","sodium-glucose-transporter-type-2-inhibition-in-anthracycline-related-cardiotoxicity-100598382","NCT07070765","Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity","Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity - SPRINT","SPRINT","Inclusion Criteria:\n\n* Patients with breast cancer between 18-70 years of age.\n* Patients with low to medium cardiovascular risk.\n* Patients scheduled for adjuvant or neo-adjuvant anthracycline therapy.\n* Patients who are able to give written informed consent to take part in the study.\n* Patients who can read and understand English.\n\nThe current thresholds for defining cardiovascular risk for patients undergoing anthracycline chemotherapy are as follows: normal resting 12-lead electrocardiogram, plasma cardiac troponin I concentration \\\u003C 99th centile, serum brain natriuretic peptide concentration \\\u003C35 pg\u002FmL or serum N-terminal pro-brain natriuretic peptide concentration \\\u003C125 pg\u002FmL, left ventricular ejection fraction \\>55%, global longitudinal strain \\>-18% and healthy life-style (normal body-mass index, non-smoker). Low cardiovascular risk will allow for the presence of one abnormal life-style factor (body-mass index indicating obesity (\\>30 kg\u002Fm2), current smoker or significant smoking history), or presence of only one of the following in the clinical history: hypertension, stage 1-2 chronic kidney disease, age 65-79 years, borderline left ventricular ejection fraction (50-54%) or elevated cardiac biomarkers. Medium cardiovascular risk will permit the combination of any 2-4 of the lifestyle or clinical history variables indicated above.\n\nExclusion Criteria:\n\n* Patients with a known intolerance of dapagliflozin\n* Patients with high cardiovascular risk as specified by the most recent cardio-oncology guidelines.\n* Patients with significant renal impairment (estimated glomerular filtration rate \\\u003C45 mL\u002Fmin\u002F1.73 m2).\n* Patients with a previous cancer diagnosis.\n* Patients with known type 1 or 2 diabetes mellitus. We will not actively screen for diabetes. This is not done in clinical practice and there have been no issues.\n* Patients with a contraindication to magnetic resonance imaging.\n* Patients with prior exposure to anthracyclines.\n* Patients who cannot read and understand English.\n* Patients who are pregnant","FEMALE",{"count":217,"type":21},70,[164],"Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.",[78],[222,223,224,225],"breast cancer","chemotherapy","anthracycline","sodium-glucose transporter type 2 inhibition",{"date":174,"type":34},{"date":228,"type":34},"2025-12-12",{"date":230,"type":21},"2028-10-31",{"name":40,"class":41},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":94,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":162,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":86},"100597968","rebalancing-the-fat-content-of-the-heart-and-muscles-100597968","NCT07065383","Rebalancing the Fat Content of the Heart and Muscles","Intramyocellular Lipid Compartments After Glucagon-like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes - Rebalancing the Fat Content of the Heart and Muscles","Re-CHARM","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of type 2 diabetes established in the previous 10 years between the ages of 20 and 75\n* HbA1c ≥ 53 mmol\u002Fmol (7%) typically on diet and\u002For metformin\u002Fsulphonylureas (and\u002For sodium-glucose cotransporter-2 inhibitors, Dipeptidyl peptidase 4 inhibitors, thiazolidinediones, but not on insulin)\n* Patients who do not meet the WHO recommendations on physical activity (≤150 minutes per week) of moderate-vigorous physical activity (MVPA)\n* Patients who have a BMI of ≥27 but with a body weight of less than 140kgs due to limitations of the scanner table weight limit\n* Current or recent (within 3 months) eGFR \\>30 mL\u002Fmin\u002F1.73m2)\n* Able to understand written and spoken English\n\nExclusion Criteria:\n\n* Any previously unknown cardiac condition other than mild valvular disease\n* Any history of known coronary artery disease (including myocardial infarction and myocardial infarction with normal coronary arteries)\n* Any relevant or untreated endocrine condition (i.e. Cushings)\n* Impaired renal function (defined as estimated glomerular filtration rate of less than 30 mL\u002Fmin\u002F1.73m2)\n* Blood pressure of more than 180\u002F100 mmHg\n* Patients on any other medication known to influence glucose or fatty acids metabolism (niacin, omega-3 fatty acids, other glucagon-like peptide-1 receptor agonists)\n* Patients with any dietary habits that may interfere with the investigation (for example high fat vegan diets, as we know form prior research that they have very different intramyocellular fat storage compared to those on no dietary preferences)\n* Patients with any history of any medical or surgical condition that in the judgement of the investigators may interfere with the exercise regime (i.e. peripheral vascular disease, arthritis), fatty acids metabolism (i.e. lipid storage diseases) or may compromise the safety of the participant (i.e. neurological syndromes for whom an intense exercise program could result in musculo-skeletal injury or accidents due to loss of balance).\n* Patients with a sensitivity to Semaglutide (known hypersensitivity, diabetic retinopathy, pregnancy, history of pancreatitis or history of any cancer)\n* Significant asthma or pulmonary disease\n* Participants unable to cycle on the ergometer\n* Unable to perform exercise testing (e.g. prosthetic limbs)\n* Pregnancy, breastfeeding or considering pregnancy.\n* Patients who have recently had gastrointestinal contrast or radionuclides\n* Inability to lie flat or remain motionless for scanning procedures\n* Patients whose girth size cannot allow them to fit in the magnetic resonance scanner (there is no set location to measure as this is different for everyone, but we have a plastic hoop that can be fitted around the largest circumference to check the fit)\n* Subjects who are not able to engage into a physical training regime or feel that they do not have the interest or sustained motivation to follow one.\n* Participants currently enrolled in other interventional clinical research\n* Participants not able to understand written or verbal English","75 Years",{"count":242,"type":21},60,[164],"Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.",[246],"Diabetes Mellitus Type 2",{"date":174,"type":34},{"date":249,"type":34},"2025-08-01",{"date":251,"type":21},"2028-07-31",{"name":40,"class":41},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":120,"sex":215,"minAge":74,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":162,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":274,"locationsCount":86},"100590861","vertigreens-investigating-the-effects-of-iron-biofortification-of-microgreens-on-iron-status-in-women-100590861","NCT06972927","VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women","Inclusion Criteria:\n\n* Healthy females\n* 15 of reproductive age (18-49)\n* 15 postmenopausal (not had their period for an entire year)\n\nExclusion Criteria:\n\nMedication exclusion criteria:\n\n* Supplementing iron or vitamin B12\n* Smoking or vaping\n* Taking anticoagulant medication (blood thinners) except for Aspirin 75mg\n\nMedical exclusion criteria:\n\n* Anyone who is planning to be pregnant, is pregnant or breastfeeding\n* Anyone with iron or vitamin B12 deficiency anaemia\n* Anyone with history of anaemia in the past 3 months that required treatment\n* Anyone who has Hb \\\u003C120 g\u002FL (12 g\u002FdL) at screening\n* Anyone with food allergies to banana, mango, pineapple, coconut\n* Anyone with coeliac disease\n* Anyone suffering from a psychiatric disorder or any type of substance abuse\n* Anyone with Type 1 diabetes and Type 2 diabetes\n* Anyone suffering from unregulated thyroid disease\n* Anyone with gastrointestinal conditions or bariatric surgery\n* Anyone with haematological conditions including Thrombocytopaenia and Sickle cell anaemia\n\nOther exclusion criteria:\n\n* Anyone with unsuitable veins for blood sampling\n* Anyone who donated blood in the last 16 weeks\n* Anyone who is unable to fluently speak, read and understand English",{"count":161,"type":21},[164],"The investigators present a diet intervention study, to be conducted as a within-subject design, to assess the effect of the provision of iron biofortified microgreens on iron intake and status in women of reproductive age and postmenopausal women. This will be investigated by providing smoothie kits for 28 days containing these microgreens and determining the impact on iron biomarkers. The investigators will also assess habitual diet, BMI, physical activity and gastrointestinal symptoms. This study will be a proof-of-concept exploratory study to explore diet based biofortification through vertical farming systems.",[263],"Iron Biomarkers\u002FStatus",[265,266,267,268,269],"vertical farming","iron biomarkers","iron status","biofortification","microgreens",{"date":174,"type":34},{"date":272,"type":34},"2025-05-01",{"date":31,"type":21},{"name":40,"class":41},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":162,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":42},"100401884","is-there-a-genetic-predisposition-for-acute-stress-induced-takotsubo-cardiomyopathy-100401884","NCT04513054","Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy","Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy: The GENETIC Study","GENETIC","Inclusion Criteria:\n\n* All patients who have been diagnosed with Takotsubo cardiomyopathy in Scotland between 2010 to date.\n* Familial cases elsewhere in the world who would be willing to participate.\n\nExclusion Criteria:\n\n* Unwillingness to participate",{"count":284,"type":21},700,[164],"Acute stress-induced (takotsubo) cardiomyopathy or broken heart syndrome presents like a heart attack, classically is triggered by intense emotional or physical stress and can have serious health consequences. In the current study the investigators wish to establish whether there is a genetic predisposition making certain people more susceptible to this condition. This could also have implications for their families.",[288],"Takotsubo Cardiomyopathy",{"date":174,"type":34},{"date":291,"type":34},"2019-03-12",{"date":293,"type":21},"2028-12-31",{"name":40,"class":41},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":120,"sex":16,"minAge":94,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":162,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":42},"100397727","the-next-leap-in-cardiac-magnetic-resonance-imagingcycling-the-field-100397727","NCT04458883","The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field","The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field The TITAN Study","TITAN","Inclusion Criteria:\n\n* Participant who is willing and able to give informed consent for participation in the study\n* Healthy volunteers willing to give informed consent for participation in the study\n* Patients diagnosed with a previous myocardial infarction\n\nExclusion Criteria:\n\n* Unwillingness to participate\n* Claustrophobia\n* Contraindication to MRI scanning such as implantable cardiac devices\n* Participants who have had a previous myocardial infarction in the past of which they may not be aware and this is discovered whilst being scanned on the 3T MRI scanner, or who may have any other cardiology condition that they were previously unaware will not be included in the healthy control group, even if they present themselves to us as \"healthy\" at the time of the study visit\n* Pregnancy\n* Body habitus that may preclude comfortable positioning of the volunteer in either of the MRI scanners (\\>50cm in diameter)\n* Participants with abnormal kidney function that will preclude them from receiving a contrast agent",{"count":304,"type":21},150,[164],"The main aim of the study is to build and test a cardiac-specific coil purposely assembled in house to suit the FFC-MRI whole-body prototype and to test if it could be used for clinical cardiac scans in human subject populations.",[308],"Myocardial Infarction",{"date":174,"type":34},{"date":311,"type":34},"2020-08-01",{"date":313,"type":21},"2027-07-31",{"name":40,"class":41},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":215,"minAge":74,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":199,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":86},"100630774","breast-tumour-size-measurement-by-field-cycling-imaging-100630774","NCT07492043","Breast Tumour Size Measurement by Field Cycling Imaging","BREVIA","Inclusion Criteria:\n\n* Females ≥ 18 years old.\n* Subjects diagnosed with DCIS on initial biopsy.\n* Lesion size \\>1 cm on imaging.\n* Subjects undergoing surgery as part of their treatment.\n* Able to fit comfortably in the scanners.\n* Able to understand written and spoken English.\n\nExclusion Criteria:\n\n* Subjects undergoing chemotherapy or hormonal therapy.\n* Individuals unable to give informed consent.\n* Contra-indications to MRI scanning such as implantable cardiac devices.\n* Known allergy to contrast agent.",{"count":323,"type":21},12,"The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is:\n\nCan FCI accurately estimate DCIS lesion size compared with histology results?\n\nParticipants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.",[78,326],"Ductal Carcinoma In Situ",[197,198,328,78],"DCIS","2026-03-19",{"date":331,"type":34},"2026-03-25",{"date":333,"type":21},"2026-04",{"date":335,"type":21},"2026-12",{"name":40,"class":41},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":86},"100593261","proving-utility-of-a-new-field-cycling-mri-prototype-in-acute-stroke-patients-100593261","NCT07004140","Proving Utility of a New Field-cycling MRI Prototype in Acute Stroke Patients","PUFFINS 3","Inclusion Criteria:\n\n* Acute stroke (\\\u003C24 hours from symptom onset).\n* NIHSS ≥4 and \\\u003C25 with cortical involvement and\u002For large vessel occlusion on baseline imaging.\n* Able to undergo 3T and FCI MRI \\\u003C24h of onset.\n* With or without thrombolysis.\n\nExclusion Criteria:\n\n* Contraindications to MRI.\n* Medically unstable.\n* Unable to comprehend or comply with instructions regarding scanning\n* Prior mRS of \\>3.\n* Identified for thrombectomy.\n* Non-stroke pathology or previous cortical infarct on CT scan \\> 1\u002F3 of middle cerebral artery territory.",{"count":345,"type":21},40,"The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can show changes in the brain within the first day of a stroke due to a blocked blood vessel or bleeding in the brain. The main question it aims to answer is:\n\n• Can FCI identify brain tissue that might recover within the first few hours after a stroke begins?\n\nParticipants will undergo a standard MRI scan and an FCI scan, as soon as possible after hospital admission.\n\nParticipants who have had a blocked blood vessel will also provide a blood sample and will have a follow up visit at 30 days for repeat of both scans and providing another blood sample.",[348],"Stroke Acute",[350,197,198],"Stroke","2026-01-26",{"date":353,"type":34},"2026-01-27",{"date":355,"type":34},"2025-09-16",{"date":203,"type":21},{"name":40,"class":41},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":120,"sex":16,"minAge":74,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":162,"phases":369,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":86},"100597988","sex-hormones-as-regulators-of-the-age--and-sex-dependent-benefits-of-caloric-restriction-100597988","NCT07065643","Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction","GendAge Weight Loss Study: Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction","GendAge","Inclusion criteria\n\n* Adults (aged over 18years) who are healthy but overweight\u002Fobese (BMI 27-45kg\u002Fm2) males and females as:\n* 15 women (age 40 or less years)\n* 15 men (age 40 or less years)\n* 15 women (age 55-65 years) in menopause\\*; not taking Hormone Replacement Therapy (HRT)\n* 15 men (age 55-65 years)\n* 15 women (age 55-65 years) in menopause; taking HRT\\*\\*\n\n  * menopause definition is no menstrual period for 12 months \\*\\*HRT inclusion criteria - women will have continuously taken oestrogen HRT for 24 months\n\nExclusion criteria:\n\nPotential volunteers will be asked to fill in a health questionnaire at the screening visit to assess their suitability for the study. This information will allow us to exclude participants.\n\nMedication exclusion criteria, current use :-\n\n• weight loss medication (e.g. GLP agonists), β-blockers, antihistamines, antipsychotics, benzodiazepines, barbiturates, melatonin, Ritalin, modafinil, soporifics, hypnotics, antiepileptic drugs, diabetes medication (e.g. metformin or insulin).\n\nSelf-reported medical exclusion criteria:\n\n* Females who are planning to be pregnant, are pregnant or are breastfeeding\n* Anyone with coeliac disease or gluten intolerance or food allergy\n* Anyone with diagnosed T1 or T2 diabetes\n* Anyone suffering from a psychiatric disorder or any type of substance abuse\n\nOther exclusion criteria\n\n* Anyone following a vegetarian or vegan diet\n* Anyone currently following a weight loss programme (that may be affecting lifestyle, physical activity \\& diet) or undergone gastric band\u002Freduction surgery; including GLP agonist (e.g. Semaglutide injection, Ozempic®).\n* Anyone currently participating in another research study\n* Anyone with unsuitable veins for blood sampling\n* Anyone who is unable to fluently speak, read and understand English\n* Anyone who is unable to comply to an alcohol-free diet for 6 weeks\n* Anyone unable to give fully informed consent","65 Years",{"count":368,"type":21},75,[164],"Obesity increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers, primarily due to elevated abdominal fat storage. With nearly two-thirds of the UK population living with overweight or obesity, there is an urgent necessity for evidence-based public health guidance to promote healthy weight. Calorie deficit can facilitate weight loss and body fat reduction, leading to health benefits, such as improved blood glucose control. Current weight management advice centres on lifestyle modification, incorporating changes to diet and physical activity to support a calorie deficit. However, existing dieting recommendations fail to consider gender or age. This is a surprising oversight, as it is well established that health outcomes vary significantly between men and women across the lifespan. Further, the menopause may have an impact on fat storage linked to changes in sex hormones. Our recent research, involving both mice and humans, has indicated that females are less responsive to weight loss and fat reduction during dieting. This study aims to understand endocrine and metabolic sex-based differences in obesity and calorie restriction, with a particular focus on women's health. We plan to conduct a diet study with 75 participants, encompassing both younger and older men and women, to monitor changes in energy expenditure and body composition using gold-standard techniques, such as doubly-labelled water. Blood and abdominal fat tissue samples will be collected to investigate how sex hormones might elucidate these differences. The aim of the study is to enhance our understanding of diet and women's health to combat obesity and promote healthy ageing.",[372,373],"Overweight and Obese Adults","Healthy",[375,376,377,378,140,379,380,381,382],"caloric restriction","low calorie diet","menopause","overweight","weigh loss","ageing","energy expenditure","body composition","2025-07-17",{"date":385,"type":34},"2025-07-18",{"date":387,"type":34},"2025-07-09",{"date":205,"type":21},{"name":40,"class":41},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":215,"minAge":121,"maxAge":51,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":399,"conditions":400,"keywords":404,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":86},"100543352","maternity-care-experiences-of-asylum-seeking-and-refugee-women-in-scotland-100543352","NCT06354751","Maternity Care Experiences of Asylum-seeking and Refugee Women in Scotland","MACAWS","( Phase one: Survey)\n\n\\- Inclusion Criteria:\n\n* Women aged 16 and over.\n* Women who are or were or had been pregnant within the last 5 years.\n* Women who were living in Scotland within the last 5 years and used National Health Service (NHS) maternity services.\n* Asylum-seeking woman at the time of being pregnant or Refugee woman at the time of being pregnant.\n* Able to understand written or spoken English, Arabic, Persian or Urdu sufficiently to complete the survey.\n\nExclusion Criteria :\n\n* Women who are economic migrants or illegal migrants or hold British citizenship at the time of being pregnant and using maternity services within last five years in Scotland.\n* Women who are asylum-seeking or refugee women and live in England or Wales or Northern Ireland.\n* Women with insufficient English, Arabic, Persian or Urdu to participate in the online survey.\n\n(Second phase: interview)\n\nInclusion Criteria for women:\n\n* Women aged 16 and over.\n* Women who can provide verbal or written consent.\n* Women who are currently pregnant or have been pregnant within the last 5 years.\n* Women who were living in Scotland within the last 5 years and used NHS maternity services.\n* Asylum-seeking woman at the time of being pregnant or Refugee woman at the time of being pregnant.\n* Able to understand written or spoken English or Arabic sufficiently to participate in the interview.\n\nExclusion Criteria for women:\n\n* Women who are economic migrants or illegal migrants or hold\u002Fheld British citizenship at the time of being pregnant and used maternity services within last five years in Scotland.\n* Women who are asylum-seeking or refugee women and live in England, Wales or Northern Ireland.\n* Women with insufficient English or Arabic to participate in the interviews.\n\nInclusion Criteria for HCPs:\n\n* Currently employed in NHS Scotland in maternity services, including:\n\n  * health care support worker,\n  * midwife,\n  * doctor and obstetrician,\n  * Maternity care leader\u002Fmanager.\n* Able to provide verbal or written consent.\n\nExclusion Criteria for HCPs:\n\n• HCPs working in other specialists (outside of the previously mentioned professions).",{"count":398,"type":21},300,"The International Organisation of Migration reports that over half (52.4%) of international migrants in Europe are women. Evidence suggests that women with immigrant backgrounds often struggle to access healthcare across the world. Among migrant women, asylum-seeking and refugee women face higher risks of poor pregnancy and birth outcomes, including babies with low birth weight, physical and\u002For mental health problems or death related to pregnancy and\u002For childbirth. Previous studies have focused on immigrant women's experiences of care during pregnancy and birth and did not differentiate between asylum seekers, refugees, and economic migrants. This can make it difficult to compare studies accurately. This study focuses on asylum-seeking and refugee women, using the definitions provided by the United Nations. Asylum-seeking women refer to women who seek protection in a country other than their own and are waiting for a decision on their status. Asylum seekers become refugees once their application has been processed and accepted.\n\nA scoping review was conducted to understand the experiences of asylum-seeking and refugee women accessing maternity care in the United Kingdom( UK), focusing on Scotland. The review found that all studies that focused on the experiences of asylum-seeking and refugee women accessing maternity care were mainly based in England. The review identified the presence of specialist migrant services in maternity settings in Scotland and across the UK. Still, there was no information on their implementation or impact on women's outcomes. Additionally, there is limited evidence in the UK on the perceptions of healthcare professionals providing care to asylum-seeking and refugee women.\n\nThis study aims to close this gap in research by exploring this area more deeply in Scotland through mixed-methods studies of surveys with asylum-seeking and refugee women and interviews with maternity care leaders, policymakers, maternity healthcare professionals, and asylum-seeking and refugee women.",[401,402,403],"Refugee","Asylum-seeking Women","Maternity",[405,406,407],"maternity care","Scotland","experiences","2025-04-10",{"date":410,"type":34},"2025-04-15",{"date":412,"type":34},"2024-05-01",{"date":414,"type":21},"2026-11-30",{"name":40,"class":41},{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":120,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":86},"100486456","detecting-early-alzheimers-using-mr-100486456","NCT05614310","Detecting Early Alzheimer's Using MR","Early Detection Of Alzheimer's Disease With GlucoCEST MRI: A Feasibility Study.","DREAMER","Inclusion Criteria:\n\nDevelopment phase:\n\nControls (development group) must:\n\n* be \\> 18 years\n* consent to the study\n* not report problems with memory.\n\nClinical phase\n\nPatients must:\n\n* be ≥ 65 years,\n* able to provide informed consent to the study\n* have been clinically diagnosed with AD by the mental health team.\n\nControls must:\n\n* be ≥ 65 years\n* able to provide consent to the study\n* have a normal score in the ADAS-cog test and the Mini Mental State Examination test (MMSE)\n* not report problems with memory.\n\nExclusion Criteria:\n\nSubjects will not be considered if they:\n\n* have a history of diabetes,\n* have history of a major stroke (mini-stroke\u002FTransient Ischaemic Attacks or lacunar stroke are acceptable),\n* have contra-indications to MRI scanning such as implantable cardiac devices\n* have family history in AD, to exclude possible gene mutations associated with AD\n* have advanced AD who lack the capacity to consent.\n* Are pregnant (for developmental phase)\n* are unable to read or speak English",{"count":242,"type":21},"Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 10% of individuals aged ≥ 65. Most available treatments aim at controlling symptoms at an early stage rather than providing a cure. Therefore, an accurate and early diagnosis of AD with appropriate management will slow the progression of the condition. Reduced cerebral glucose levels have been observed in patients with early AD. Glucose hypometabolism can be assessed by administering a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG), and imaging with PET (positron emission tomography). The high cost and limited availability of PET-CT (PET - computed tomography) still hamper its general clinical application. Moreover, the use of radioactive tracers in combination with the additional ionizing radiation of CT is not suitable for repeated measurements. Therefore, currently, the provisional diagnosis of AD is still based on the combination of clinical history, neurological examination, cognitive testing over a period of time, and structural neuroimaging. This has major time and resource implications.\n\nA radically different and highly innovative means for imaging glucose with magnetic resonance imaging (MRI) has now been established, exploiting the interaction between hydroxyl protons in glucose and the protons in water; the method is termed glucose Chemical Exchange Saturation Transfer (glucoCEST). GlucoCEST MRI is a method that has no reliance on radiolabelled glucose analogues and could become widely implemented in clinic practice. We therefore aim to investigate the potential of glucoCEST MRI in Alzheimer's disease.",[427],"Alzheimer Disease",[429,430],"Magnetic Resonance Imaging (MRI)","Glucose Chemical Exchange Saturation Transfer (CEST)","2025-03-25",{"date":433,"type":34},"2025-03-30",{"date":435,"type":34},"2022-11-15",{"date":437,"type":21},"2025-12-31",{"name":40,"class":41},{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":447,"targetDuration":449,"studyType":22,"phases":4,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":458,"locationsCount":86},"100308765","establishing-the-incidence-of-tako-tsubo-cardiomyopathy-in-scotland-100308765","NCT03299569","Establishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland","Establishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland - the STARR Study","STARR","Inclusion Criteria:\n\n* All patients diagnosed with Takotsubo cardiomyopathy\n\nExclusion Criteria:\n\n* NA",{"count":448,"type":21},800,"13 Years","Acute stress-induced (Takotsubo cardiomyopathy) presents like a heart attack and is triggered by intense emotional or physical stress. Although coronary arteries are unobstructed, it has been suggested that the risk of death is similar to a myocardial infarction. The purpose of the STARR study is to identify all cases of Takotsubo in Scotland since 2010 and assess its epidemiology and outcomes.",[288,308],"2025-03-19",{"date":454,"type":34},"2025-03-24",{"date":456,"type":34},"2016-07-29",{"date":293,"type":21},{"name":40,"class":41},{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":483},"100506651","pain-and-opioids-after-surgery-100506651","NCT05877157","Pain AND Opioids After Surgery","Pain and Opioids After Surgery (PANDOS) Study","PANDOS","Inclusion Criteria:\n\n* hospitalised adult patients (18 years and older) undergoing any inpatient surgery (elective or emergency) during the designated study week where an anaesthetist is involved (general anaesthetic, sedation, local anaesthetic).\n\nAble to understand and has capacity to give written informed consent\n\nExclusion Criteria:\n\n* American Society of Anaesthesiologists (ASA) grade V or VI\n* Refusal to participate.\n* Lack of comprehension of validated questionnaires or inability to complete the follow-up for any reason.\n* Lack of capacity to give written informed consent",{"count":468,"type":21},10000,"The aim of this study is to document the perioperative opioid use and its safety in the UK and countries in Europe and to describe its association with surgical complications, persistent pain and quality of life. In an international, prospective, observational cohort study, data about the perioperative pain management will be collected in all eligible hospitalised adult patients who undergo surgery in a designated \"study week\" in as many hospitals as possible in Europe. Baseline data will be collected, and participants followed up at one week, and at three and twelve months post-operatively. The primary outcome will be opioid use at three months after surgery. Secondary outcomes will include opioid use during the preoperative month (preoperative use), during surgery and up to one week after surgery (or discharge, whichever is earlier), and up to the end of the postoperative year. Additional secondary outcomes are the incidence of preoperative pain, persistent pain with\u002Fwithout the presence of neuropathic components, quality of life and surgical complications. The potential association between opioid use and pain outcomes will be investigated. This study could help to develop strategies to improve quality of care, through pain management, for patients undergoing surgery.",[471,472,473,474],"Opioid Use","Pain, Chronic","Pain, Postoperative","Quality of Life","2024-12-18",{"date":477,"type":34},"2024-12-24",{"date":479,"type":34},"2023-09-25",{"date":481,"type":21},"2026-09-30",{"name":40,"class":41},4,{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":86},"100488579","radiofrequency-denervation-and-brain-imaging-100488579","NCT05641948","Radiofrequency Denervation and Brain Imaging","Radiofrequency Denervation and Brain Structure, Function And Connectivity In Chronic Low Back Pain Patients","Inclusion Criteria:\n\n* Age 18 years or older\n* Chronic moderate to severe cLBP (defined by average pain intensity of ≥ 4 in the 11 point Numerical Pain rating scale and a minimum duration of 1 year)\n* Identified by clinical team as suitable for RFD pathway\n* Predominantly nociceptive pain (as defined by PainDetect score ≤12)\n* Stable on current analgesic regime\n* Able to communicate in English\n* Has the capacity to and agrees to give informed consent for participation in the study\n* Positive response to a single diagnostic MBB with 1 ml or less of local anaesthetic (bupivacaine 0.5%) at each level. (a positive response is defined as ≥80% pain relief at 3 hours, based on patient reported assessment)\n\nExclusion Criteria:\n\n* Any patient whose physical condition will preclude them from lying still for the duration of the brain scan.\n* Contraindication to magnetic resonance scanning such as an implantable cardiac device.\n* Women who are, or may be, pregnant. (Pregnant patients do not undergo pain procedures under radiological guidance as per routine clinical care)\n* Significant anxiety and depression (as defined by HADS score ≥ 9)\n* Clinical suspicion that alternative diagnosis is the reason for LBP\n* Presence of chronic primary pain conditions (Fibromyalgia, chronic widespread pain, Complex Regional Pain Syndrome, Chronic Primary Headache, Orofacial pain, Chronic primary visceral pian and Chronic Primary musculoskeletal pain as defined by ICD-11 classification)\n* Presence of thoracic or neck pain\n* History of previous RF denervation\n* Regular use of two or more dependence forming drugs (opioids, gabapentinoids, Benzodiazepines, tricyclics antidepressants and z-drugs)",{"count":345,"type":21},"The goal of this observational study is to learn about changes in brain and its activity of following radiofrequency denervation treatment for chronic low back pain. The main question it aims to answer are:\n\n* report the magnitude of the brain changes following radiofrequency treatment for low back pain.\n* identify changes unique to radiofrequency treatment\n\nPatients with nociceptive type low back pain of moderate to severe intensity will be identified to undergo radiofrequency treatment. They will have 3 MRI scans - Baseline, after the diagnostic injections and 3 months after radiofrequency treatment. They will also fill questions relating to their pain, disability and health related quality of life.",[494],"Low Back Pain, Mechanical",[496,497],"Neuroimaging","Radiofrequency denervation",{"date":477,"type":34},{"date":500,"type":34},"2023-04-03",{"date":481,"type":21},{"name":40,"class":41},{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":86},"100446259","nerve-composition-of-human-lumbar-dorsal-primary-rami-and-its-medial-branch-100446259","NCT05091112","Nerve Composition of Human Lumbar Dorsal Primary Rami and Its Medial Branch","Inclusion Criteria:\n\n* Be aged 18 or over\n* be able to give informed consent\n* scheduled to undergo lumbar spinal surgery\n\nExclusion Criteria:\n\n* Children under 18 years old\n* Vulnerable adults\n* Adults with incapacity\n* Inability to provide informed consent\n* History of previous spinal surgery\n* history of previous RF ablation for low back pain\n* has COVID-19 or displaying symptoms of COVID-19",{"count":510,"type":21},20,"The purpose of the study is to understand the composition of the nerves supplying the facet joints in low back.",[513,514],"Lumbar Facet Arthrosis","Nerve Degeneration",{"date":477,"type":34},{"date":517,"type":34},"2022-03-08",{"date":519,"type":21},"2024-12-31",{"name":40,"class":41},{"id":522,"slug":523,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":120,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":529,"conditions":530,"keywords":535,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":548,"leadSponsor":550,"locationsCount":86},"100571519","continuous-heart-rate-variability-monitoring-in-doctors-understanding-patterns-of-stress-and-recovery-and-their-relationship-with-self-reported-resilience-burnout-and-wellbeing-100571519","NCT06721312","Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relationship With Self-reported Resilience, Burnout and Wellbeing.","HEART-ED","Inclusion Criteria:\n\n* Working within NHS Grampian\n* Access to a smartphone\n\nExclusion Criteria:\n\n* Cardiac arrhythmias\u002Fendocrine disease.\n* Prescription beta blockers, calcium channel blockers, ACE inhibitors, benzodiazepines, antidepressants and antianxiety medications.\n* Insufficient non-working time prior to study commencement.",{"count":242,"type":21},"Burnout is an increasing concern in the medical professions. This study aims to utilise established, validated self-report measures combined with continuous heart rate variability measurements to better understand the stress and recovery patterns experienced by doctors that may contribute to burnout.\n\nThis mixed methods study design will consist of an ecological momentary assessment phase where participants will complete commonly used and validated real-time subjective measures while concurrently wearing a heart rate variability monitor to provide an objective measure of stress. Following on from this, participants of interest will be invited to participate in semi structured interviews to further explore their experiences of stress and recovery.",[531,532,533,534],"Burnout","Burnout Syndrome","Occupational Stress","Stress",[536,537,538,539,540,541,542,543],"Heart rate variability","HRV","occupational stress","resilience","fatigue","wellbeing","stress","burnout","2024-12-06",{"date":546,"type":34},"2024-12-11",{"date":178,"type":21},{"date":549,"type":21},"2025-10-31",{"name":40,"class":41},{"id":552,"slug":553,"hasResults":11,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":120,"sex":16,"minAge":74,"maxAge":189,"enrollmentInfo":558,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":199,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":4},"100538494","assessment-of-microorganisms-and-host-response-in-liver-diseases-100538494","NCT06291571","Assessment of Microorganisms and Host Response In Liver Diseases","MILD","Inclusion Criteria:\n\n1. Willing and able to provide informed consent\n2. Definitive diagnosis of specific liver disease utilising clinical, biochemical, and radiological tests\n3. Male or female aged between 18-70 years\n4. Able to understand written or verbal information in English\n\nExclusion Criteria:\n\n1. Pregnancy and breastfeeding\n2. Treatment with antibiotics in the last month\n3. Treatment with steroids or immunosuppressive drugs in the last month\n4. Regular consumption of over-the-counter prebiotics and probiotics from pharmacies or other retailers in the last month.\n5. Known gastrointestinal disease, including but not limited to ulcerative colitis, Crohn's disease, coeliac disease, microscopic colitis, diverticulitis, irritable bowel syndrome\n6. Patients diagnosed with cancer who are on chemotherapy, radiotherapy, or immunotherapy within the last 3 months",{"count":559,"type":21},200,"The normal human gut is home to millions of microbes including bacteria, fungi, and viruses, collectively forming the gut microbiota, which exists in harmony within us. Much research is still required to fully understand the contribution of microbes resident in the large intestine in liver diseases. The liver receives blood from the gut carrying all the necessary nutrients needed for our body but also has to deal with toxins derived from the microbes residing in the intestines. The gut microbiota is altered in liver disease. We still do not know clearly how this change impacts liver function and the health of liver patients. The purpose of our study is to answer this question by assessing the gut microbiota using modern microbiological and molecular methods. By studying the alterations in the gut microbiota in patients with liver disease we can understand how they affect our immune system and metabolism. This will help design novel medicinal products to prevent and treat liver disease.",[562,563],"Gut Microbiome","Liver Diseases","2024-05-08",{"date":566,"type":34},"2024-05-09",{"date":568,"type":21},"2024-06-01",{"date":570,"type":21},"2030-03-01",{"name":40,"class":41},{"id":573,"slug":574,"hasResults":11,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":11,"sex":16,"minAge":121,"maxAge":578,"enrollmentInfo":579,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":581,"conditions":582,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":86},"100485767","exploiting-the-gut-microbiota-and-its-metabolites-in-pelvic-cancer-100485767","NCT05605353","Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer","Inclusion Criteria:\n\n1. Patients willing to consent\n2. Any patient who is being treated in NHS Grampian for a pelvic cancer (Colorectal, urological or gynaecological) above 16 years of age\n\nExclusion Criteria:\n\n1. patients who are not willing to consent to be involved\n2. Malignancies from other sources or anatomical locations\n3. Patients who lack the understanding of the study to obtain appropriate levels of consen","99 Years",{"count":580,"type":21},450,"The large intestine is the last part of the digestive tract. It absorbs water and dietary substances. However, it is also where most of our bacteria are resident. These bacteria are important for our health and influence many different diseases, including Colon Cancer, Ulcerative Colitis and Crohn's disease. The gut bacteria can also potentially influence responses to treatments in other cancers by helping to change the responses to radiotherapy and chemotherapy. The interactions between these bacteria and the rest of our cells are only now becoming understood and there is little research on the interactions between these bacteria and cancer radiotherapy treatments in pelvic cancer.\n\nWe will therefore explore this in more detail. We will ask for samples of the patient's poo before their treatment for pelvic cancers. This will include patients with bladder, prostate, cervical, ovarian, womb or colorectal cancers. By doing so we will be able to compare the profile of gut bacteria with responses to treatments, thereby increasing our understanding of the colonic bacteria.\n\nTo do this we process the poo specimens to remove the bacterial genetic material (DNA) of the bacteria and process it on a machine to read the genetic code and also study the metabolites that they will produce. We can then make a direct comparison between different samples of the relative numbers of different bacteria present. In some cases, we will compare this to metabolites and inflammatory and immune markers identified in a blood sample. This work might help future patients by determining what are the best bacteria to have in the colon during cancer treatments. These could potentially be given to patients, before their cancer treatment, in the form of probiotic medications, should there be an improvement demonstrated in our research. Alternatively we could alter the patients' intakes of specific dietary fibres to boost these bacteria specifically.",[583],"Pelvic Neoplasm","2023-05-12",{"date":586,"type":34},"2023-05-16",{"date":588,"type":34},"2023-03-01",{"date":590,"type":21},"2029-05-31",{"name":40,"class":41},""]